{"entity":{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","aka":["Nat Med","src-nature-medicine"],"tldr":"Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.","summary":"Nature Medicine appears monthly and publishes phase 1 and 2 trials with deep translational analysis (MagnetisMM-3 elranatamab in this corpus), circulating tumour DNA and multi-cancer early-detection studies, large medical-AI validations and consensus reporting guidelines for AI in medicine. Hybrid access with a Springer Nature open-access option.","asOf":"2026-09-09","links":[{"label":"Nature Medicine cancer","url":"https://www.nature.com/nm/research-articles?subject=cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Translational medicine including cancer vaccines, AI diagnostics and phase 1 to 3 trials with mechanistic depth. Access: Paywalled; abstracts free; some open access."],"publisher":"Springer Nature","url":"https://www.nature.com/nm/","issn":"1078-8956","scope":"translational medicine","access":"hybrid","founded":1995,"impactFactor":{"value":58.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Medicine","Nat Med"]},"route":"/journals/nature-medicine/","neighbours":{"paper":[{"id":"paper-bensch-nat-med","kind":"paper","name":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","route":"/key-papers/paper-bensch-nat-med/"},{"id":"paper-vorontsov-nat-med","kind":"paper","name":"A foundation model for clinical-grade computational pathology and rare cancers detection","route":"/key-papers/paper-vorontsov-nat-med/"},{"id":"paper-lu-nat-med","kind":"paper","name":"A visual-language foundation model for computational pathology","route":"/key-papers/paper-lu-nat-med/"},{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/"},{"id":"paper-durham-nat-med","kind":"paper","name":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","route":"/key-papers/paper-durham-nat-med/"},{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/"},{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/"},{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/"},{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/"},{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/"},{"id":"paper-gandara-blood-tmb-atezolizumab-nat-med-2018","kind":"paper","name":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","route":"/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/"},{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/"},{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/"},{"id":"paper-batlle-nat-med","kind":"paper","name":"Cancer stem cells revisited","route":"/key-papers/paper-batlle-nat-med/"},{"id":"paper-gupta-nat-med","kind":"paper","name":"Cancer stem cells: mirage or reality?","route":"/key-papers/paper-gupta-nat-med/"},{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/"},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/"},{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/"},{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/"},{"id":"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021","kind":"paper","name":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)","route":"/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/"},{"id":"paper-mackensen-nat-med","kind":"paper","name":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","route":"/key-papers/paper-mackensen-nat-med/"},{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/"},{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/"},{"id":"paper-mahalingam-nat-med","kind":"paper","name":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","route":"/key-papers/paper-mahalingam-nat-med/"},{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/"},{"id":"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)","route":"/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/"},{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/"},{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/"},{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/"},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/"},{"id":"paper-rodon-nat-med","kind":"paper","name":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","route":"/key-papers/paper-rodon-nat-med/"},{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/"},{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/"},{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/"},{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/"},{"id":"paper-davies-nat-med","kind":"paper","name":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","route":"/key-papers/paper-davies-nat-med/"},{"id":"paper-bonnet-nat-med","kind":"paper","name":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","route":"/key-papers/paper-bonnet-nat-med/"},{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/"},{"id":"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021","kind":"paper","name":"JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma","route":"/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/"},{"id":"paper-romero-nat-med","kind":"paper","name":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","route":"/key-papers/paper-romero-nat-med/"},{"id":"paper-brown-nat-med","kind":"paper","name":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","route":"/key-papers/paper-brown-nat-med/"},{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/"},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/"},{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/"},{"id":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","kind":"paper","name":"Molecular determinants of resistance to antiandrogen therapy","route":"/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/"},{"id":"paper-sicklick-nat-med","kind":"paper","name":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","route":"/key-papers/paper-sicklick-nat-med/"},{"id":"paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","kind":"paper","name":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","route":"/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/"},{"id":"paper-garralda-nat-med","kind":"paper","name":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","route":"/key-papers/paper-garralda-nat-med/"},{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/"},{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/"},{"id":"paper-dizman-nat-med","kind":"paper","name":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","route":"/key-papers/paper-dizman-nat-med/"},{"id":"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)","route":"/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/"},{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/"},{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/"},{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/"},{"id":"paper-burd-nat-med","kind":"paper","name":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","route":"/key-papers/paper-burd-nat-med/"},{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/"},{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/"},{"id":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","kind":"paper","name":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","route":"/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/"},{"id":"paper-collisson-pancreatic-subtypes-nat-med-2011","kind":"paper","name":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","route":"/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/"},{"id":"paper-cms-guinney-nat-med-2015","kind":"paper","name":"The consensus molecular subtypes of colorectal cancer","route":"/key-papers/paper-cms-guinney-nat-med-2015/"},{"id":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","kind":"paper","name":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","route":"/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/"},{"id":"paper-o-dwyer-nat-med","kind":"paper","name":"The NCI-MATCH trial: lessons for precision oncology","route":"/key-papers/paper-o-dwyer-nat-med/"},{"id":"paper-kilburn-nat-med","kind":"paper","name":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","route":"/key-papers/paper-kilburn-nat-med/"},{"id":"paper-elara-tisagenlecleucel-follicular-nat-med-2022","kind":"paper","name":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","route":"/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/"},{"id":"paper-todo-g47delta-glioblastoma-natmed-2022","kind":"paper","name":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","route":"/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/"},{"id":"paper-chen-nat-med","kind":"paper","name":"Towards a general-purpose foundation model for computational pathology","route":"/key-papers/paper-chen-nat-med/"},{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/"},{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/"},{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/"},{"id":"paper-rothwell-nat-med","kind":"paper","name":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","route":"/key-papers/paper-rothwell-nat-med/"},{"id":"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","kind":"paper","name":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","route":"/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/"},{"id":"paper-bissell-nat-med","kind":"paper","name":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression","route":"/key-papers/paper-bissell-nat-med/"}],"person":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/"},{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/"},{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/"},{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/"}]}}